Targeted RNA or BDNF gene transfer protects against frataxin deficiency

Ian Fyfe, Research Highlight: Nature Reviews Neurology (2016), doi:10.1038/nrneurol.2016.19, Published online 26 February 2016

In two recently published studies, the pathological consequences of this FXN mutation have been successfully counteracted in in vitro and in vivo models with the use of different approaches, each with therapeutical potential.

-In the first study, David Corey and colleagues introduced synthetic anti‑GAA duplex RNA molecules into patient-derived cells that had the FXN mutation, this increased expression of frataxin by up to sixfold. They believe that their findings are a starting point for the development of RNA-based drugs, and are looking to take the next step.

-The second study, led by Javier Diaz-Nido, did not involve targeting the FXN gene, but aimed to block the apoptosis. Neurotrophic factors are potent suppressors of neuronal apoptosis, they were able to protect neurons from death triggered by frataxin gene silencing”. Now, they plan to test whether there is a synergy between two gene therapy strategies: one based on frataxin gene replacement and the other based on neurotrophic factor gene delivery

ORIGINAL ARTICLES:
-Katsu-Jiménez, Y. et al. Gene transfer of brain derived neurotrophic factor (BDNF) prevents neurodegeneration triggered by frataxin deficiency. Mol. Ther.
-Li, L. et al. Activating frataxin expression by repeat-targeted nucleic acids. Nat. Comm.


Targeted RNA or BDNF gene transfer protects against frataxin deficiency

References:

-Li, L. et al. Activating frataxin expression by repeat-targeted nucleic acids. Nat. Comm. http://dx.doi.org/10.1038/ncomms10606

-Katsu-Jiménez, Y. et al. Gene transfer of brain derived neurotrophic factor (BDNF) prevents neurodegeneration triggered by frataxin deficiency. Mol. Ther. http://dx.doi.org/10.1038/mt.2016.32